Sugi Predict

Sugi Predict / Targets / MAP3K11

MAP3K11

Mitogen-activated protein kinase kinase kinase 11 · Q16584 · MAP3K11 on Sugi Atlas →

28,106 patent compounds predicted against MAP3K11, 18,528 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL298617 SCHEMBL298617 0.58 4/20
SCHEMBL31684 SCHEMBL31684 0.48 3/20
SCHEMBL260885 SCHEMBL260885 0.42 3/20
SCHEMBL386619 SCHEMBL386619 0.90 2/20
SCHEMBL386620 SCHEMBL386620 0.90 2/20
SCHEMBL386843 SCHEMBL386843 0.84 2/20
SCHEMBL386844 SCHEMBL386844 0.84 2/20
SCHEMBL387966 SCHEMBL387966 0.84 2/20
SCHEMBL386814 SCHEMBL386814 0.82 2/20
SCHEMBL386815 SCHEMBL386815 0.82 2/20
SCHEMBL386859 SCHEMBL386859 0.81 2/20
SCHEMBL388011 SCHEMBL388011 0.78 2/20
SCHEMBL387734 SCHEMBL387734 0.77 2/20
SCHEMBL387665 SCHEMBL387665 0.77 2/20
SCHEMBL387666 SCHEMBL387666 0.77 2/20
SCHEMBL387742 SCHEMBL387742 0.72 2/20
SCHEMBL387743 SCHEMBL387743 0.72 2/20
SCHEMBL387793 SCHEMBL387793 0.70 2/20
SCHEMBL387935 SCHEMBL387935 0.59 2/20
SCHEMBL387986 SCHEMBL387986 0.56 2/20

Clinical trials — most relevant to MAP3K11 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations PHASE2ACTIVE_NOT_RECRUITING
A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors PHASE1/PHASE2ACTIVE_NOT_RECRUITING
HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies PHASE1/PHASE2RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations PHASE2RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer PHASE2UNKNOWN
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma PHASE1/PHASE2SUSPENDED
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE2COMPLETED
Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) PHASE1COMPLETED
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma PHASE1COMPLETED
Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Evaluation of Human Melanocytes After the Use of PRP Versus Fractional CO2 Laser in Vitiligo nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Clinical Genetics Branch Eligibility Screening Survey nanNOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies nanENROLLING_BY_INVITATION
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a MAP3K11 binder may also engage these)

ProteinNameSimilarity
Q80XI6 — 1.000 Q80XI6 →
Q66HA1 — 1.000 Q66HA1 →
MAP3K10 Mitogen-activated protein kinase kinase kinase 10 0.997 landscape →
D3ZG83 — 0.996 D3ZG83 →
MAP3K9 Mitogen-activated protein kinase kinase kinase 9 0.994 landscape →
TNK2 Activated CDC42 kinase 1 0.993 landscape →
Q8VDG6 — 0.992 Q8VDG6 →
Q66L42 — 0.992 Q66L42 →
Q2LGB3 — 0.992 Q2LGB3 →
A2AEV7 — 0.991 A2AEV7 →
P58660 — 0.990 P58660 →
Q9UQQ2 — 0.990 Q9UQQ2 →
Q99ML2 — 0.990 Q99ML2 →
Q8K330 — 0.989 Q8K330 →
Q9WVS8 — 0.989 Q9WVS8 →
Q8WWN8 — 0.989 Q8WWN8 →
Q8BLS7 — 0.989 Q8BLS7 →
TNK1 Non-receptor tyrosine-protein kinase TNK1 0.988 landscape →
A1L3T7 — 0.988 A1L3T7 →
TESK1 Dual specificity testis-specific protein kinase 1 0.988 landscape →
A6QQ70 — 0.988 A6QQ70 →
Q9BRR9 — 0.988 Q9BRR9 →
Q9BWT7 — 0.988 Q9BWT7 →
A5PKL7 — 0.988 A5PKL7 →
A0A8I3PMN2 — 0.988 A0A8I3PMN2 →
Q9Y242 — 0.988 Q9Y242 →
Q3UYR4 — 0.987 Q3UYR4 →
O54967 — 0.987 O54967 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.987 landscape →
Q3KP66 — 0.987 Q3KP66 →